H. Poyntz

发表

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis

H. McShane, E. Stylianou, K. Griffiths, 2014, Tuberculosis.

IMMUNOLOGICAL ASPECTS Non-tuberculous mycobacteria have diverse effects on BCG ef ﬁ cacy against Mycobacterium tuberculosis

H. McShane, E. Stylianou, Ths, 2014 .

Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

A. Hill, A. Milicic, H. Fletcher, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy.

D. Knight, I. Hermans, F. Ronchese, 2014, Nature chemical biology.

Genetic regulation of antibody responsiveness to immunization in substrains of BALB/c mice

L. Weyrich, R. Jáuregui, M. Linterman, 2018, Immunology and cell biology.

Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases

L. Weyrich, W. Young, L. V. D. van den Elsen, 2017, Clinical & translational immunology.

A feasibility study: association between gut microbiota enterotype and antibody response to seasonal trivalent influenza vaccine in adults

M. Weatherall, W. Young, S. Poppitt, 2018, Clinical & translational immunology.

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection

H. McShane, A. Hill, E. Stylianou, 2012, PloS one.

Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses

A. Hill, M. Bregu, Alexandra J. Spencer, 2018, Scientific Reports.

of a Novel Heterosubtypic Influenza A Vaccine, MVA2NP1M1

A. Hill, A. Milicic, H. Fletcher, 2011 .

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery☆

H. McShane, Joel Meyer, H. Fletcher, 2013, Vaccine.

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

H. McShane, E. Stylianou, L. Stockdale, 2015, Vaccine.

Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice

H. McShane, H. Fletcher, E. Stylianou, 2013, PloS one.

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults

H. McShane, A. Lawrie, A. Hill, 2012, Human vaccines & immunotherapeutics.

Potential Association Between Dietary Fibre and Humoral Response to the Seasonal Influenza Vaccine

M. Weatherall, W. Young, S. Poppitt, 2021, Frontiers in Immunology.

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults

A. Winston, R. Koup, D. Douek, 2011, BMJ Open.

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb).

H. McShane, P. Marsh, H. Fletcher, 2013, Tuberculosis.

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy

H. McShane, A. Hill, A. Minassian, 2011, PloS one.